Progel Vascular Sealant

Inclusion Criteria: * 1\. Subject must be ≥ 18 years of age. * 2\. Subject is scheduled for elective, primary thoracic surgery involving the aortic valve, ascending aorta, or aortic arch on cardiopulmonary bypass. * 3\. Subject has an expected life expectancy\> 6 months. * 4\. Subject is willing and able to comply with all aspects of the study including follow-up schedule. * 5\. Subject or authorized representative, has the ability to provide voluntary written informed consent. Intra-operative Inclusion Criteria: * 1\. Subject is able to undergo an antegrade cardioplegia injection for evaluation of a leak at the aortic anastomotic site(s) during the procedure. * 2\. Following this injection, subject has a leaking site where a topical sealant/hemostatic agent may be used to control bleeding. Exclusion Criteria: * 1\. Subject has Type A or other acute thoracic aortic dissection. * 2\. Subject has undergone prior thoracic surgery (open thoracotomy not including interventional cardiology procedures). * 3\. Subject is undergoing a planned concomitant procedure other than coronary artery bypass graft (CABG). * 4\. Subject has a previous organ transplant. * 5\. Subject has known or suspected preoperative coagulation disorder. * 6\. Subject is allergic to human thrombin or has a history of allergic reactions after application of human thrombin. * 7\. Subject is allergic to protamine. * 8\. Subject has a Left Ventricular Assist Device (LVAD) or planned to receive an LVAD. * 9\. Subject is undergoing emergency surgery. * 10\. Subject is in chronic renal failure. * 11\. Subject has a hematocrit \< 21% pre-operatively. * 12\. Subject has a serum creatinine ≥2.5 mg/dl at baseline or is currently on dialysis. * 13\. Subject has a cardiac ejection fraction \<25%. * 14\. Subject is scheduled for another cardiac surgery within 30 days of enrollment. * 15\. Subject has an active or latent infection which is systemic or at the intended surgery site. * 16\. Subject is immuno-compromised such as that resulting from chronic oral steroid use, chemotherapeutic agents, or immune deficiency disorders. * 17\. Subject is pregnant by a positive pregnancy test or has plans to become pregnant during the study period or is currently breast-feeding. * 18\. Subject is unwilling to receive blood products. * 19\. Subject has participated in another investigational research study within 30 days of enrollment. * 20\. In the opinion of the investigator, the subject has a clinical condition that would preclude the use of the study device, preclude the subject from completing the follow-up requirements, or would complicate the evaluation of this study.